<DOC>
	<DOCNO>NCT01395654</DOCNO>
	<brief_summary>Despite availability effective anti-tuberculosis agent exist treat illness , hepatotoxicity first-line drug anti-tuberculosis medication ( ATT ) isoniazid ( INH ) , rifampin ( RIF ) , pyrazinamide ( PZA ) uncommon limit use . There consensus method reintroduction anti-TB medication . The risk reintroduce anti-TB medication could hazardous . There several difference guideline ATS , BTS Task Force European Respiratory Society , WHO International Union Against Tuberculosis Lung Disease method reintroduce anti-TB medication . The investigator plan prospective study evaluate outcome safety reintroduction anti-TB medication resolution hepatitis anti-TB treatment among TB patient investigator hospital .</brief_summary>
	<brief_title>Reintroduction Regimens After Hepatitis During Anti-tuberculosis Treatment</brief_title>
	<detailed_description>Tuberculosis ( TB ) remain leading health problem develop developed country . Despite availability effective chemotherapeutic agent exist treat illness , hepatotoxicity first-line drug anti-tuberculosis medication ( ATT ) isoniazid ( INH ) , rifampin ( RIF ) , pyrazinamide ( PZA ) uncommon limit use . In case confirm moderate severe drug-induced hepatotoxicity , treatment interrupt reintroduced hepatotoxicity resolve . There consensus method reintroduction anti-TB medication . The risk reintroduce anti-TB medication could hazardous . There several difference guideline ATS , BTS Task Force European Respiratory Society , WHO International Union Against Tuberculosis Lung Disease method reintroduce anti-TB medication . We plan prospective study evaluate outcome safety reintroduction anti-TB medication resolution hepatitis anti-TB treatment among TB patient hospital .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis , Pulmonary</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Isoniazid</mesh_term>
	<mesh_term>Pyrazinamide</mesh_term>
	<mesh_term>Antitubercular Agents</mesh_term>
	<criteria>Hepatitis antituberculosis treatment Hold RMP , INH PZA hepatitis Age &gt; = 18 year old HIV ( ) Tbilirubin &lt; 2.5 mg/dL No allergy RMP , INH PZA Liver cirrhosis , child B C Pregnancy breast feed Life expectation &lt; 1 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>